Prestige Brands’ OTC Revenue Climbs With Boost In Advertising
This article was originally published in The Tan Sheet
Executive Summary
Prestige CEO Mannelly attributes the success of Clear Eyes, Chloraseptic, Compound W and Little Remedies to a $1 million increase in advertising and promotions. The OTC division’s net revenue soar 55.7% to $79.2 million.
You may also be interested in...
In Brief
Prestige Brands gains from acquisitions
J&J Quality Issues, Hill Concerns Spill Over To Blacksmith's PediaCare
The impact of McNeil Consumer Healthcare's quality control lapses extends to Blacksmith Brands, which becomes a congressional inquiry target after recalling PediaCare products manufactured at one of the Johnson & Johnson subsidiary's plants
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.